Other systemic atrophy primarily affecting central nervous system in neoplastic disease
ICD-10 G13.1 is a billable code used to indicate a diagnosis of other systemic atrophy primarily affecting central nervous system in neoplastic disease.
G13.1 refers to systemic atrophy of the central nervous system that occurs in the context of neoplastic diseases. This condition can manifest as a result of primary or metastatic tumors affecting the brain and spinal cord, leading to neurodegeneration. The atrophy may be due to direct tumor invasion, pressure effects, or secondary to treatment modalities such as chemotherapy or radiation therapy. Patients may present with a variety of neurological symptoms, including cognitive decline, motor dysfunction, and sensory disturbances. The condition is often associated with other systemic effects of cancer, such as cachexia, which can further complicate the clinical picture. Accurate diagnosis requires a thorough neurological examination, imaging studies, and sometimes biopsy to determine the underlying neoplastic process. Understanding the interplay between the neoplasm and the resultant neurological atrophy is crucial for effective management and coding.
Detailed neurological assessments, imaging results, and treatment history.
Patients with brain tumors presenting with cognitive decline or motor deficits.
Ensure clear documentation of neurological findings and their relation to the neoplastic disease.
Comprehensive cancer staging, treatment plans, and side effects of therapies.
Patients undergoing treatment for cancer who develop neurological symptoms.
Document the impact of cancer treatment on neurological function.
Used for follow-up visits of patients with G13.1 for neurological assessments.
Document the patient's neurological status, treatment history, and any new symptoms.
Neurologists should ensure comprehensive evaluations are documented.
Accurate coding of G13.1 is crucial for proper reimbursement, tracking of disease prevalence, and ensuring that patients receive appropriate care based on their neurological status related to neoplastic diseases.
